Halozyme Therapeutics (DE:RV7)

Halozyme (DE:RV7) Income Statement


Halozyme Income Statement

Last quarter (Q3 2022), Halozyme's total revenue was $208.98M, an increase of 80.42% from the same quarter last year. In Q3, Halozyme's net income was $61.63M. See Halozyme’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 580.62M$ 443.31M$ 267.59M$ 195.99M$ 151.86M$ 316.61M
Cost of Revenue
$ 118.77M$ 81.41M$ 43.37M$ 45.55M$ 10.14M$ 31.15M
Gross Profit
$ 461.85M$ 361.90M$ 224.23M$ 150.45M$ 141.73M$ 285.46M
Operating Expense
$ 212.30M$ 86.00M$ 79.97M$ 218.06M$ 211.06M$ 204.46M
Operating Income
$ 249.56M$ 275.90M$ 144.25M$ -67.61M$ -69.33M$ 81.00M
Net Non Operating Interest Income Expense
$ -14.43M$ -7.53M$ -20.38M$ -11.63M$ -18.04M$ -21.98M
Other Income Expense
$ -2.19M$ -19.86M$ 5.42M$ 6.99M$ 7.58M$ 2.59M
Pretax Income
$ 232.94M$ 248.52M$ 129.30M$ -72.25M$ -79.79M$ 61.61M
Tax Provision
$ 21.74M$ -154.19M$ 217.00K$ -11.00K$ 537.00K$ -1.36M
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ 211.20M$ 402.71M$ 129.09M$ -72.24M$ -80.33M$ 62.97M
Basic EPS
$ 1.08$ 2.86$ 0.95$ -0.50$ -0.56$ 0.46
Diluted EPS
$ 1.05$ 2.74$ 0.91$ -0.50$ -0.56$ 0.45
Basic Average Shares
$ 415.73M$ 140.65M$ 136.21M$ 144.33M$ 143.60M$ 136.42M
Diluted Average Shares
$ 427.72M$ 146.80M$ 141.46M$ 144.33M$ 143.60M$ 139.07M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
$ 0.42$ 2.00----
Rent Expense Supplemental
Total Expenses
$ 331.07M$ 167.41M$ 123.34M$ 263.60M$ 221.19M$ 235.61M
Net Income From Continuing And Discontinued Operation
$ 211.20M$ 402.71M$ 129.09M$ -72.24M$ -80.33M$ 62.97M
Normalized Income
$ 213.35M$ 417.21M$ 123.67M$ -79.22M$ -85.86M$ 61.42M
Interest Expense
$ 14.43M$ 7.53M$ 20.38M$ 11.63M$ 18.04M$ 21.98M
$ 247.37M$ 256.04M$ 149.68M$ -60.62M$ -61.75M$ 83.59M
$ 290.67M$ 259.04M$ 152.96M$ -56.56M$ -59.36M$ 85.75M
Currency in USD

Halozyme Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis